All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Enclomiphene and MK-677 stacked: what the science says

damnqoob

TikTok creator

1.5K viewsWatch on TikTok→

Quick answer

The creator is self-administering a stack of enclomiphene, a selective estrogen receptor modulator used off-label to raise endogenous testosterone, alongside MK-677, an oral ghrelin mimetic that elevates growth hormone and IGF-1. Neither compound is FDA-approved for the purpose implied in the video, and their combined effects on insulin sensitivity, the hypothalamic-pituitary-gonadal axis, and cardiovascular markers in otherwise healthy men have not been studied in controlled trials. Without baseline labs and clinical monitoring, identifying adverse effects early is unlikely.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @qoob85 actually say?

Not much, technically. The transcript is almost entirely aesthetic ambition, not a pharmacological claim. The creator says they want to get so jacked that people say "what the fuck is that" rather than compliment a "pretty physique." The real information lives in the hashtags and caption: they're running a first cycle stacking enclomiphene with MK-677, framing it under the "nattyplus" umbrella that has become code for hormone-adjacent compounds that aren't classic anabolic steroids.

That framing matters. "Nattyplus" exists specifically to blur the line between natural and enhanced, and both enclomiphene and MK-677 sit squarely in enhanced territory. This video doesn't explain what either compound does, what doses are being used, what monitoring is in place, or what the risks are. It's a vibe check, not a health disclosure.

Does the science back this up?

The science on these two compounds is real but incomplete, and neither one is approved by the FDA for bodybuilding use. That's not a technicality, it's a meaningful gap in the evidence.

Enclomiphene is the trans-isomer of clomiphene citrate. It works by blocking estrogen receptors in the hypothalamus, which signals the pituitary to produce more LH and FSH, which in turn stimulates endogenous testosterone production. Kim et al. (2013, Fertility and Sterility) showed enclomiphene raised testosterone in men with secondary hypogonadism without suppressing spermatogenesis. That's a real effect. But the population studied was hypogonadal men under clinical supervision, not healthy young men chasing body composition goals.

MK-677 (ibutamoren) is a ghrelin receptor agonist that increases growth hormone and IGF-1 secretion. Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) found it raised GH and IGF-1 levels in older adults but also increased fasting glucose and insulin resistance. It is not a SARM, not a peptide in the strict sense, and not approved for human use outside of trials.

What did they get wrong (or right)?

The creator didn't make specific pharmacological claims, so there's nothing factually wrong in the spoken words. The problem is what's implied and omitted.

Running enclomiphene in a healthy, presumably eugonadal young man is not the same as using it therapeutically. If testosterone is already normal, stimulating more LH and FSH may not produce the dramatic gains the "nattyplus" community suggests. The effect size for body composition in eugonadal men is not well-established in published literature.

MK-677 does raise GH pulse amplitude, and users often report improved sleep quality and appetite, but the appetite increase is significant. Weight gain from MK-677 frequently includes water retention and fat, not just lean mass. Calling this a clean physique compound is optimistic reading of the data.

Stacking both compounds also means two mechanisms affecting hormone axes simultaneously, with no publicly shared bloodwork, no physician oversight mentioned, and no acknowledgment of known side effects including elevated prolactin, insulin resistance, and potential suppression of the HPG axis over time.

What should you actually know?

Both compounds have real physiological effects and real risks that a 15-second TikTok with a catchphrase cannot cover.

  • Enclomiphene is not FDA-approved for male hypogonadism as a standalone drug. Androxal, its branded form, failed to gain FDA approval in 2015 for reasons including incomplete safety data. Compounded enclomiphene is now widely available through telehealth, but compounded does not mean equivalent to a reviewed and approved drug.
  • MK-677 is explicitly on the World Anti-Doping Agency prohibited list and is not approved for human use by the FDA. It is sold as a "research chemical," which is a legal workaround, not a safety guarantee.
  • The "nattyplus" framing normalizes hormone manipulation in young men without the context that long-term effects on the HPG axis for healthy men using these compounds are genuinely unknown.
  • Anyone considering either compound should have baseline bloodwork, including total testosterone, LH, FSH, estradiol, fasting glucose, and IGF-1, and should work with a licensed provider who can monitor changes over time.

Wanting an extreme physique is a legitimate goal. Pursuing it through unmonitored hormonal intervention is a gamble on your endocrine system that no TikTok comment section can help you troubleshoot.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Enclomiphene and MK-677 stacked: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Enclomiphene and MK-677 stacked: what the science says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim verdict

The useful answer behind this video

Claim being checked

The creator is self-administering a stack of enclomiphene, a selective estrogen receptor modulator used off-label to raise endogenous testosterone, alongside MK-677, an oral ghrelin mimetic that elevates growth hormone and IGF-1.

FormBlends verdict

The creator is self-administering a stack of enclomiphene, a selective estrogen receptor modulator used off-label to raise endogenous testosterone, alongside MK-677, an oral ghrelin mimetic that elevates growth hormone and IGF-1. Neither compound is FDA-approved for the purpose implied in the video, and their combined effects on insulin sensitivity, the hypothalamic-pituitary-gonadal axis, and cardiovascular markers in otherwise healthy men have not been studied in controlled trials. Without baseline labs and clinical monitoring, identifying adverse effects early is unlikely.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator is self-administering a stack of enclomiphene, a selective estrogen receptor modulator used off-label to raise endogenous testosterone, alongside MK-677, an oral ghrelin mimetic that elevates growth hormone and IGF-1. Neither compound is FDA-approved for the purpose implied in the video, and their combined effects on insulin sensitivity, the hypothalamic-pituitary-gonadal axis, and cardiovascular markers in otherwise healthy men have not been studied in controlled trials. Without baseline labs and clinical monitoring, identifying adverse effects early is unlikely.
  • Enclomiphene's most robust clinical data comes from hypogonadal men, not healthy men optimizing physique. Kim et al. (2013, Fertility and Sterility) found efficacy in secondary hypogonadism specifically.
  • MK-677 raises GH and IGF-1 but also increases fasting glucose and insulin levels. Nass et al. (2008, JCEM) documented these metabolic trade-offs in a controlled 12-month trial.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Enclomiphene's most robust clinical data comes from hypogonadal men, not healthy men optimizing physique. Kim et al. (2013, Fertility and Sterility) found efficacy in secondary hypogonadism specifically.
  • MK-677 raises GH and IGF-1 but also increases fasting glucose and insulin levels. Nass et al. (2008, JCEM) documented these metabolic trade-offs in a controlled 12-month trial.
  • Androxal, the branded enclomiphene product, was rejected by the FDA in 2015 due to insufficient safety and efficacy data, meaning compounded enclomiphene has never completed the full regulatory review process.
  • MK-677 appears on the WADA prohibited substances list under 'other anabolic agents' and is classified as a research chemical in the United States, not an approved therapeutic.
  • The 'nattyplus' label has no clinical definition. Both compounds in this stack have direct endocrine effects and cannot be reasonably framed as natural or minimally intervening.
  • Stacking an SERM with a ghrelin agonist simultaneously affects two major hormonal axes without published safety data for that specific combination in healthy men.
  • Anyone self-administering either compound without baseline and follow-up labs for testosterone, estradiol, LH, FSH, IGF-1, and fasting glucose has no reliable way to detect adverse hormonal or metabolic changes early.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

damnqoob · TikTok creator

1.5K views on this video

Running my first cycle let’s see how this goes 🙂‍↔️#nattyornot #gymtok #nattyplus #enclomiphene #mk677

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by damnqoob, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.